科创板禾元生物董事长杨代常：上市后会加速临床管线推进

Core Viewpoint - The chairman and general manager of He Yuan Bio expressed that the company will accelerate the progress of its international clinical pipelines following its listing on the STAR Market [1] Company Overview - He Yuan Bio has a total of 8 drug pipelines currently under research [1] - The core product, recombinant human albumin injection (HY1001), is expected to be approved for market by July 2025, targeting the indication of "hypoalbuminemia due to liver cirrhosis" [1] - In addition to the core product, 5 other products are in clinical research stages, while multiple products are in preclinical research stages [1]